New Treatment Opportunity to Help Preserve Vision in Diabetics


Joslin research boosts evidence for a new class of treatments to help preserve vision in people with diabetes, including diabetic macular edema and retinopathy.

[Read more…]

Virtual Reality a New Tool for Evaluating Balance in Glaucoma Patients

virtual reality tool to test balance

People living with diabetes are nearly twice as likely to get glaucoma. Falls are a leading cause of injury and death, and the risk rises when you have an eye disease. Now, there is a new tool for evaluating balance – and it’s pretty cool.

[Read more…]

FDA Approves Eylea to Treat Diabetic Retinopathy and DME


Breakthrough therapy designation granted to Eylea for the treatment of Diabetic Retinopathy with Diabetic Macular Edema. Eylea is administered by a physician once a month for the first five treatments and then once every two months. [Read more…]

FDA Expands the Approved Use for Lucentis to Treat Diabetic Retinopathy in Patients with Diabetic Macular Edema


Diabetic retinopathy is the most common diabetic eye disease and is a leading cause of blindness in adults in the United States. According to the Centers for Disease Control and Prevention, diabetes (type 1 and type 2) affects more than 29 million people in the United States and is the leading cause of new blindness among people ages 20 to 74 years. In 2008, 33 percent of adults with diabetes aged 40 years or older had some form of DR. In some cases of DR with DME, abnormal new blood vessels grow on the surface of the retina. Severe vision loss or blindness can occur if the new blood vessels break.
[Read more…]